Clinical Trial Update: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating trilaciclib in combination with sacituzumab govitecan for EGFR-mutated advanced non-small cell lung cancer. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Status: RECRUITING